Evolent Health (NYSE:EVH) Price Target Cut to $18.00 by Analysts at JMP Securities

Evolent Health (NYSE:EVH) had its target price reduced by analysts at JMP Securities from $27.00 to $18.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the technology company’s stock. JMP Securities’ price target would indicate a potential upside of 44.35% from the company’s current price.

EVH has been the topic of several other research reports. Barclays reduced their target price on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $20.00 target price on shares of Evolent Health in a report on Tuesday, November 12th. Oppenheimer decreased their price target on Evolent Health from $34.00 to $28.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Stephens downgraded shares of Evolent Health from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $38.00 to $16.00 in a research report on Friday, November 8th. Finally, Citigroup reduced their price target on Evolent Health from $33.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $24.17.

Evolent Health Stock Down 1.0 %

EVH traded down $0.13 on Friday, hitting $12.47. 283,556 shares of the company were exchanged, compared to its average volume of 1,251,693. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -13.70 and a beta of 1.45. The firm has a 50-day moving average price of $13.13 and a two-hundred day moving average price of $21.09. Evolent Health has a twelve month low of $10.53 and a twelve month high of $35.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Quarry LP purchased a new position in shares of Evolent Health in the second quarter valued at $32,000. Covestor Ltd lifted its holdings in Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its position in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Evolent Health during the second quarter valued at about $61,000. Finally, Quest Partners LLC purchased a new stake in shares of Evolent Health during the second quarter worth about $87,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.